LOUISVILLE, Ky. (Jan. 30, 2012) – Advanced Cancer Therapeutics, LLC (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, Monday announced that Dr. Gilles Tapolsky, ACT’s Chief Scientific Officer, has been selected to present at the World Cancer Metabolism Summit to be held Feb. 1-2, 2012, in Washington, D.C.
The presentation will be held on Thursday, Feb. 2, 2012, from 3:30–4 p.m. Dr. Tapolsky will present “Preclinical Characterization of Antagonists of 6-Phosphofructo-2-Kinase That Suppress Glucose Metabolism and Tumor Growth.”
ACT is developing inhibitors of glycolysis targeting 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), a cancer metabolism target identified as essential for cancer cell growth and licensed by ACT from the James Graham Brown Cancer Center. High glucose consumption is observed in most cancers. PFKFB3 is the enzyme involved in the first irreversible step of glycolysis, and has been validated as a relevant cancer metabolism target. Inhibitors of the PFKFB3 block glucose uptake and inhibit tumor growth.
About Advanced Cancer Therapeutics (ACT):
ACT is a privately held company dedicated to advancing novel therapeutics for the prevention and treatment of cancer. ACT has successfully established a unique and innovative business model with the University of Louisville’s James Graham Brown Cancer Center (Brown Cancer Center) whereby ACT is able to obtain exclusive worldwide licenses to novel cancer therapeutics discovered at Brown Cancer Center under preset business terms. ACT then fast-tracks these discoveries, including the selection process for partnership, commercialization and manufacture, to the pharmaceutical industry, and ultimately to the patients who need them. Led by Dr. Don Miller, the Brown Cancer Center employs over fifty scientists focused on the discovery and advancement of breakthrough cancer therapeutics for patients suffering from cancer. For more information, please visit www.advancedcancertherapeutics.com.